Quick answers
- What is Carisoprodol used for?
- The FDA-approved label (Soma, Viatris Specialty LLC, August 29, 2025) says: “SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Carisoprodol have a boxed warning?
- No. None of the 46 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Carisoprodol?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Carisoprodol been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Carisoprodol?
- 26 companies list prescription products of Carisoprodol in the FDA NDC Directory, including Bryant Ranch Prepack, Asclemed USA, Inc. and PD-Rx Pharmaceuticals, Inc..
What Carisoprodol is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration […]. …
— FDA label: Soma, Viatris Specialty LLC, effective August 29, 2025. Read the full label on DailyMed →
The FDA has 46 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 46 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 54 in the FDA NDC Directory |
| Brand names | Soma |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| carisoprodol 250 mg tablet | Generic | $0.5313 per tablet |
| carisoprodol 350 mg tablet | Generic | $0.0728 per tablet |
| carisoprodol 350 mg tablet | Brand: Soma | $11.30 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack13 products
- Asclemed USA, Inc.3 products
- PD-Rx Pharmaceuticals, Inc.3 products
- Proficient Rx LP3 products
- Aphena Pharma Solutions - Tennessee, LLC2 products
- Wilshire Pharmaceuticals, Inc.2 products
- Direct_Rx2 products
- NuCare Pharmaceuticals, Inc.2 products
- A-S Medication Solutions2 products
- Westminster Pharmaceuticals, LLC2 products
- Rising Pharma Holdings, Inc.2 products
- Remedyrepack Inc.2 products
- Viatris Specialty LLC2 products
- Aurobindo Pharma Limited2 products
- ScieGen Pharmaceuticals, Inc.1 product
- DirectRx1 product
- Advanced Rx Pharmacy of Tennessee, LLC1 product
- Medsource Pharmaceuticals1 product
- Ingenus Pharmaceuticals, LLC1 product
- Northwind Health Company, LLC1 product
- Oxford Pharmaceuticals, LLC1 product
- Granulation Technology, Inc.1 product
- St. Mary's Medical Park Pharmacy1 product
- Chartwell RX, LLC1 product
- Vensun Pharmaceuticals, Inc.1 product
- Mylan Pharmaceuticals Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA011792 SOMA | Mylan Speciality LP | April 9, 1959 | 27, latest April 4, 2019 2019: Labeling · 2018: Labeling · 2015: Labeling |
Generic approvals (8)
- ANDA040188Oxford Pharms · March 7, 1997
- ANDA040245Chartwell Rx · September 8, 1997
- ANDA040823Ingenus Pharms LLC · October 22, 2008
- ANDA040792Aurobindo Pharma · August 6, 2009
- ANDA203374Sciegen Pharms · January 27, 2014
- ANDA205126Heritage · July 8, 2015
- ANDA207237Mpp Pharma · May 11, 2017
- ANDA211789Pharmazone · October 20, 2021
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 197446, 213695, 730794, 730918 |
|---|---|
| SPL set ID of the quoted label | 6297cf20-830a-11dc-94c8-0002a5d5c51b |
| FDA labels (SPL) | 46 |
| FDA applications | NDA011792, 8 ANDA |
| Active ingredients (FDA) | CARISOPRODOL |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Soma, Viatris Specialty LLC, effective August 29, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →